Literature DB >> 2777104

Malignant transformation of an iris melanocytoma. A case report.

A P Cialdini1, J A Sahel, A E Jalkh, J J Weiter, K Zakka, D M Albert.   

Abstract

A 34-year-old Caucasian woman was diagnosed as having a pigmented iris tumor showing recent growth and satellite lesions. The tumor was associated with pigmentation of the anterior chamber angle and secondary unilateral glaucoma. After local excision, histopathologic studies revealed the plump polyhedral cells typical of melanocytoma. However, the examination of additional sections showed evidence of malignancy. The diagnosis of a melanocytoma that transformed into malignant melanoma was made and later confirmed by electron microscopic studies. Following surgical excision of the tumor, the eye maintained normal intraocular pressure. There was no evidence of recurrence 4 years after surgery.

Entities:  

Mesh:

Year:  1989        PMID: 2777104     DOI: 10.1007/BF02169411

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  21 in total

1.  MELANOCYTES, MELANOCYTIC NEVI, AND MELANOCYTOMAS.

Authors:  L E ZIMMERMAN
Journal:  Invest Ophthalmol       Date:  1965-02

2.  The prognosis of primary tumors of the iris treated by iridectomy.

Authors:  B RONES; L E ZIMMERMAN
Journal:  AMA Arch Ophthalmol       Date:  1958-08

3.  Melanocytoma of the choroid clinically simulating a malignant melanoma.

Authors:  J A Shields; R L Font
Journal:  Arch Ophthalmol       Date:  1972-04

4.  Melanomalytic glaucoma. Report of a case.

Authors:  M Yanoff; H G Scheie
Journal:  Arch Ophthalmol       Date:  1970-10

5.  Iris melanocytoma with secondary glaucoma.

Authors:  M Nakazawa; M Tamai
Journal:  Am J Ophthalmol       Date:  1984-06       Impact factor: 5.258

6.  Necrotic melanocytoma of iris with secondary glaucoma.

Authors:  J A Shields; W H Annesley; G L Spaeth
Journal:  Am J Ophthalmol       Date:  1977-12       Impact factor: 5.258

7.  Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors.

Authors:  C L Shields; J A Shields; M B Shields; J J Augsburger
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

8.  Tumors of the anterior uvea. I. Metastasizing malignant melanoma of the iris.

Authors:  M S Sunba; A H Rahi; G Morgan
Journal:  Arch Ophthalmol       Date:  1980-01

9.  Are most iris "melanomas' really nevi? A clinicopathologic study of 189 lesions.

Authors:  F A Jakobiec; G Silbert
Journal:  Arch Ophthalmol       Date:  1981-12

10.  Anterior uveal melanomas and intraocular pressure.

Authors:  M B Shields; G K Klintworth
Journal:  Ophthalmology       Date:  1980-06       Impact factor: 12.079

View more
  6 in total

1.  Pupil sparing excision of an atypical iris melanocytoma induces remission of secondary glaucoma.

Authors:  J C Zhao; D N Zacks; E S Gragoudas; L R Pasquale
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

Review 2.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

3.  Malignant transformation of iris melanocytoma to iris ring melanoma.

Authors:  Mandeep S Sagoo; Prithvi Mruthyunjaya; Ian Cree; Philip J Luthert; John L Hungerford
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

4.  A case of iris melanocytoma transformed to malignant melanoma.

Authors:  Ryo Inoue; Yoshitsugu Saishin; Chiharu Shima; Hiroshi Yoshikawa; Nobuyuki Ohguro; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2009-05-31       Impact factor: 2.447

5.  Melanocytoma of the ciliary body misdiagnosed as iridodialysis.

Authors:  Moosang Kim; Seung-Jun Lee
Journal:  Clin Ophthalmol       Date:  2014-05-29

6.  Vitrectomy as a treatment modality in vitreous seeding secondary to ciliary body melanocytoma.

Authors:  P Mahesh Shanmugam; Ishfaq A Sofi; Pradeep Sagar; Vinaya K Konana; Rajesh Ramanjulu
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.